Cytokines in inflammatory malignant fibrous histiocytoma presenting with leukemoid reaction.
Inflammatory malignant fibrous histiocytomas (IMFH) are rare tumors and are frequently associated with leukocytosis. In rare cases, leukemoid reactions were attributed to tumor production of unidentified hematopoietic factors. In this study, we used immunohistochemical techniques to show cytokine immunoreactivity in the malignant cells of two cases of IMFH presenting with leukemoid reactions and compared them with two malignant fibrous histocytomas, noninflammatory type. All four tumors stained positively for stem cell factor (SCF), granulocyte colony-stimulating factor (G-CSF), interleukin-2 (IL-2), IL-4, IL-5, interferon-alpha (IFN-alpha), and insulin-like growth factor-I. Other cytokines detected only in the two IMFH included IL-6, IL-7, IL-8, IFN-gamma, and keratinocyte growth factor. Granulocyte-macrophage-CSF, IL-3, and transforming growth factor-beta staining was present in one of the two IMFH tumors and was not present in the noninflammatory tumors. The immunohistochemical staining was localized to the malignant cells, suggesting deregulated cytokine expression consistent with their monocytic/histocytic origin. Expression of certain cytokines in the IMFH may account for the local inflammatory infiltrate, tumor fibrosis, and the aggressive nature of the malignant cells. We also detected elevated serum levels of SCF, G-CSF, IL-6, and tumor necrosis factor in one or both of the IMFH patients. These latter observations may explain the bone marrow hypercellularity and other paraneoplastic symptoms, including fever, malaise, and weight loss, observed in both patients. Different cytokines present in the two IMFH tumors appear to be responsible for the eosinophilic leukemoid reaction observed in one case and for the granulocytic leukemoid reaction observed in the other patient. They may also be responsible for expansion of the tumor-cell population, fibroblast proliferation, and enhanced secretion of extracellular collagen.
Melhem
M F
MF
Department of Pathology, University of Pittsburgh School of Medicine, PA.
Meisler
A I
AI
Saito
R
R
Finley
G G
GG
Hockman
H R
HR
Koski
R A
RA
D000368:Aged; D001853:Bone Marrow / Q000473:pathology*; D016207:Cytokines / Q000032:analysis* / Q000097:blood*; D016179:Granulocyte Colony-Stimulating Factor / Q000032:analysis; D006133:Growth Substances / Q000032:analysis; D016298:Hematopoietic Cell Growth Factors / Q000032:analysis; D018219:Histiocytoma, Benign Fibrous / Q000097:blood* / Q000175:diagnosis / Q000473:pathology* / Q000601:surgery; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D016898:Interferon-alpha / Q000032:analysis; D007378:Interleukins / Q000032:analysis*; D007938:Leukemia / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D012186:Retroperitoneal Neoplasms / Q000097:blood / Q000175:diagnosis / Q000473:pathology* / Q000601:surgery; D019089:Stem Cell Factor
D016207:Cytokines; D006133:Growth Substances; D016298:Hematopoietic Cell Growth Factors; D016898:Interferon-alpha; D007378:Interleukins; D019089:Stem Cell Factor; D016179:Granulocyte Colony-Stimulating Factor; D007334:Insulin-Like Growth Factor I